...
首页> 外文期刊>薬物動態 >Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase:prediction of metabolism and toxicity of drugs in humans
【24h】

Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase:prediction of metabolism and toxicity of drugs in humans

机译:基因工程细菌细胞与NADPH-细胞色素P450还原酶共表达人类细胞色素P450:预测人类药物的代谢和毒性

获取原文
获取原文并翻译 | 示例
           

摘要

Genetically engineered bacterial cells expressing human cytochrome P450(CYP) have been developed as new tools to predict the metabolism and toxicity of drugs in humans.There are various host cells for the heterologous expression of a form of CYP.Among them,bacterial cells such as Escherichia coli(C.coli) have advantages with regard to ease of use and high yield of protein.CYP protein could be first expressed by the modification of the N-terminal amino acid sequence in E.coli cells in 1991.Since then,many forms of human CYP have been successfully expressedin E.coli cells.Since the E.coli cells do not possess endogeneous electron transport systems to support the full cataytic activity of CYP,E.coli strains co-expressing both human CYP and NADPH-cytochrome P450 reductase (OR) have been established.Each form of CYP expressed in the E.coli cells efficiently catalyzed the oxidation of a representative substrate at an efficient rate,indicating that the OR was sufficiently expressed to support the catalytic activity of CYP.According to the studies performed so far,the modification of the N-terminal amino acid sequence of CYP did not seem to affect the catalytic properties of CYP.The human CYP expressed in the E.coli cells were applicable for studies to determine a metabolic pathway(s) of drugs and to estimate kinmetic parameters of drug metabolism by human CYP.Drug-drug interactionscaused by in-hibition of the metabolism of drugs by human CYP could also be examined by in vitro inhiibtion studies with CYP expressed in the E.coli cells. Recently,human CYP was co-expressed with the OR in Salmonella typhimurium (S.typhimurium) cells used for mutation assay (Ames test) by applying the technology for the expression of human CYP and the OR in E.coli cells,to evaluate whether chemicals incuding drugs are metabolically activated by human CYP and sow mutagenicity. These strains of bacteria are considered as useful tools to study the mtabolism and the toxicity of drugs in humans.
机译:已开发出表达人类细胞色素P450(CYP)的基因工程细菌细胞,作为预测人类药物代谢和毒性的新工具。存在多种宿主细胞,可异源表达CYP。大肠杆菌在蛋白质的易用性和高产量方面具有优势。CYP蛋白可以通过在1991年对大肠杆菌细胞的N端氨基酸序列进行修饰来表达。从那时起,许多CYP形式的人CYP已成功表达在大肠杆菌细胞中。还原酶(OR)已被建立。在大肠杆菌细胞中表达的每种CYP形式均以有效速率有效催化代表性底物的氧化,表明该OR被充分表达以支持迄今为止的研究表明,CYP的N末端氨基酸序列的修饰似乎并不影响CYP的催化性能。在大肠杆菌细胞中表达的人CYP适用于确定人的CYP的药物代谢途径和估计药物代谢的运动学参数的研究。通过CYP的体外抑制研究也可以检查由人CYP抑制药物代谢所引起的药物相互作用在大肠杆菌细胞中表达。最近,通过应用人类CYP和OR技术在大肠杆菌细胞中表达人CYP和OR,在表达突变法(Ames试验)的鼠伤寒沙门氏菌(S. typhimurium)细胞中与人CYP共表达。涉及化学物质的药物通过人CYP代谢激活,并具有致突变性。这些细菌菌株被认为是研究药物在人体中的代谢和毒性的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号